Inici › Leucèmia › Illinois › Chicago
Assaigs clínics de Leucèmia a Chicago, IL
16 estudis de Leucèmia busquen participants en centres de Chicago i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
ReclutantFase 1/2
- The University of Chicago Medical Center, Chicago
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
ReclutantFase 3
- Research Site, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
ReclutantFase 1/2
- University of Chicago, Chicago
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
ReclutantFase 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
ReclutantFase 2
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
ReclutantFase 1/2
- Research Site, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
Reclutant
- Northwestern University Feinberg School of Medicine, Chicago
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
ReclutantFase 2
- University of Chicago Medical Center, Chicago
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
ReclutantEstudi observacional
- Lurie Children's Hospital-Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
ReclutantFase 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
ReclutantFase 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
Reclutant
- UChicago Medicine Comprehensive Cancer Center, Chicago
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
ReclutantFase 1/2
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Reclutant
- University of Chicago Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Chicago
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
ReclutantFase 1
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Assaigs de Leucèmia en altres ciutats
- Houston, TX28 estudis
- Boston, MA25 estudis
- New York City, NY19 estudis
- Los Angeles, CA16 estudis
- Durham, NC13 estudis
- Baldwin Park, CA12 estudis
- Columbus, OH12 estudis
- Nashville, TN12 estudis
- Philadelphia, PA12 estudis
- Milwaukee, WI11 estudis
- Atlanta, GA11 estudis
- Seattle, WA11 estudis
Altres estudis a Chicago
- Càncer de pulmó de cèl·lules no petites61 estudis
- Càncer de mama58 estudis
- Càncer (tots els tipus)51 estudis
- Càncer metastàtic45 estudis
- Càncer de pròstata45 estudis
- Obesitat41 estudis
- Càncer de pulmó41 estudis
- Càncer d'ovari36 estudis
- Ictus34 estudis
- Càncer colorrectal33 estudis
- Insuficiència cardíaca31 estudis
- Sobrepès28 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.